Literature DB >> 32792634

Surf early to higher tides: surfactant therapy to optimize tidal volume, lung recruitment, and iNO response.

Girija G Konduri1, Satyan Lakshminrusimha2.   

Abstract

Inhaled nitric oxide is approved by FDA for the management of hypoxemic respiratory failure in term and near-term infants. However, approximately a third of patients treated with inhaled nitric oxide fail to have a sustained improvement in oxygenation. Recruitment of the lung with surfactant enables optimal delivery of nitric oxide to the alveolar space leading to effective pulmonary vasodilation.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32792634      PMCID： PMC8220734          DOI： 10.1038/s41372-020-0764-4

Source DB:  PubMed          Journal:  J Perinatol        ISSN： 0743-8346            Impact factor:   2.521


  7 in total

1.  Morbidity of Persistent Pulmonary Hypertension of the Newborn in the First Year of Life.

Authors:  Martina A Steurer; Rebecca J Baer; Scott Oltman; Kelli K Ryckman; Sky K Feuer; Elizabeth Rogers; Roberta L Keller; Laura L Jelliffe-Pawlowski
Journal:  J Pediatr       Date:  2019-08-06       Impact factor: 4.406

2.  Inhaled nitric oxide and gentle ventilation in the treatment of pulmonary hypertension of the newborn--a single-center, 5-year experience.

Authors:  Anju Gupta; Shantanu Rastogi; Rakesh Sahni; Alok Bhutada; David Bateman; Deepa Rastogi; Arthur Smerling; Jen-Tien Wung
Journal:  J Perinatol       Date:  2002-09       Impact factor: 2.521

3.  Persistent Pulmonary Hypertension of the Newborn in Late Preterm and Term Infants in California.

Authors:  Martina A Steurer; Laura L Jelliffe-Pawlowski; Rebecca J Baer; J Colin Partridge; Elizabeth E Rogers; Roberta L Keller
Journal:  Pediatrics       Date:  2016-12-01       Impact factor: 7.124

4.  Bosentan as Adjunctive Therapy for Persistent Pulmonary Hypertension of the Newborn: Results of the Randomized Multicenter Placebo-Controlled Exploratory Trial.

Authors:  Robin H Steinhorn; Jeffrey Fineman; Andjela Kusic-Pajic; Peter Cornelisse; Martine Gehin; Pegah Nowbakht; Christine M Pierce; Maurice Beghetti
Journal:  J Pediatr       Date:  2016-08-05       Impact factor: 4.406

5.  Surfactant replacement therapy for meconium aspiration syndrome.

Authors:  R D Findlay; H W Taeusch; F J Walther
Journal:  Pediatrics       Date:  1996-01       Impact factor: 7.124

6.  Early inhaled nitric oxide therapy for term and near-term newborn infants with hypoxic respiratory failure: neurodevelopmental follow-up.

Authors:  G Ganesh Konduri; Betty Vohr; Charlene Robertson; Gregory M Sokol; Alfonso Solimano; Joel Singer; Richard A Ehrenkranz; Nalini Singhal; Linda L Wright; Krisa Van Meurs; Eileen Stork; Haresh Kirpalani; Abraham Peliowski; Yvette Johnson
Journal:  J Pediatr       Date:  2007-03       Impact factor: 4.406

7.  Impact of early surfactant and inhaled nitric oxide therapies on outcomes in term/late preterm neonates with moderate hypoxic respiratory failure.

Authors:  G G Konduri; G M Sokol; K P Van Meurs; J Singer; N Ambalavanan; T Lee; A Solimano
Journal:  J Perinatol       Date:  2013-07-18       Impact factor: 2.521
  7 in total
  1 in total

Review 1.  Pathophysiology and Management of Persistent Pulmonary Hypertension of the Newborn.

Authors:  Yogen Singh; Satyan Lakshminrusimha
Journal:  Clin Perinatol       Date:  2021-08       Impact factor: 2.642
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.